Prognostic factors, patterns of failure and re-irradiation in hypofractionated stereotactic radiotherapy-treated brain metastases from non-small cell lung cancer.

ABSTRACT:

Background

Hypofractionated stereotactic radiotherapy (fSRT) is increasingly used for brain metastases (BMs) from non-small cell lung cancer (NSCLC). However, relevant data concerning treatment outcomes of fSRT and clinical utility of re-irradiation using fSRT (re-fSRT) remain scarce.

Methods

Consecutive NSCLC patients with fSRT-treated BMs from May 2018 to May 2022 were included. The cumulative incidence of intracranial local recurrence (iLR), intracranial progressive disease (iPD) and symptomatic radiation necrosis (sRN) were calculated from the initiation of fSRT, choosing death as the competing event. Patients with limited iPD (number ≤5 and size ≤3 cm) and without iLR developed within 12 months, were classified as re-fSRT candidates. The clinical value of re-fSRT and do

SUBMITTER: Xu D 

PROVIDER: S-EPMC12409328 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature